Skip to Main Content

Paper Details

Acquired HER2 mutations in ER<sup>+</sup> metastatic breast cancer confer resistance to estrogen receptor-directed therapies.
Nat Genet
149
2019
CDK4, CDK6, ER, ER mutations, ER+, HER2, HER2 kinase, HER2 mutations, aromatase, breast cancers, estrogen, estrogen receptor, fulvestrant, metastatic breast cancer, neratinib, palbociclib, patients, people, tamoxifen, tumors
Author NameAffiliation
Michael S CuocoBroad Institute of MIT and Harvard
Samuel S FreemanDana-Farber Cancer Institute
Samuel S FreemanHarvard Medical School
Samuel S FreemanDana-Farber Cancer Institute
Samuel S FreemanBroad Institute of MIT and Harvard
Samuel S FreemanHarvard Medical School
Samuel S FreemanBroad Institute of MIT and Harvard
Orit Rozenblatt-RosenBroad Institute of MIT and Harvard
Cynthia X MaSiteman Cancer Center, Washington University School of Medicine
Aviv RegevBroad Institute of MIT and Harvard
Aviv RegevHoward Hughes Medical Institute and Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology
Aviv RegevBroad Institute of MIT and Harvard
Aviv RegevHoward Hughes Medical Institute and Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology
Eric P WinerDana-Farber Cancer Institute
Eric P WinerHarvard Medical School
Eric P WinerBrigham and Women's Hospital
Nancy U LinDana-Farber Cancer Institute
Nancy U LinBrigham and Women's Hospital
Nancy U LinHarvard Medical School
Nikhil WagleCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute
Nikhil WagleDana-Farber Cancer Institute
Nikhil WagleHarvard Medical School
Nikhil WagleBroad Institute of MIT and Harvard
Nikhil WagleBrigham and Women's Hospital
Nikhil WagleCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute
Nikhil WagleDana-Farber Cancer Institute
Nikhil WagleHarvard Medical School
Nikhil WagleBroad Institute of MIT and Harvard
Nikhil WagleBrigham and Women's Hospital
  • 1 - 29

Datasets

Release 1.2